![David Hanley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Hanley
Corporate Officer/Principal en NUVATION BIO INC. .
Fortuna: 37 200 $ al 31/05/2024
Cargos activos de David Hanley
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
NUVATION BIO INC. | Corporate Officer/Principal | 01/06/2021 | - |
Historial de carrera de David Hanley
Antiguos cargos conocidos de David Hanley.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BIOXCEL THERAPEUTICS, INC. | Corporate Officer/Principal | 04/09/2018 | 01/05/2021 |
RADIUS HEALTH, INC. | Corporate Officer/Principal | 01/08/2014 | 01/08/2018 |
THE MEDICINES COMPANY | Corporate Officer/Principal | 01/06/2011 | 01/08/2014 |
Formación de David Hanley.
Virginia Commonwealth University | Undergraduate Degree |
University of Utah | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Operativa
Corporate Officer/Principal | 4 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BIOXCEL THERAPEUTICS, INC. | Health Technology |
NUVATION BIO INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Radius Health, Inc.
![]() Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
The Medicines Co.
![]() The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- David Hanley
- Experiencia